Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced today that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. The acquired ANDAs include niche otic and ophthalmic pharmaceuticals.
Daniel Carbery, President of Amring, stated, “We are pleased with our progress during the past year and look forward to realizing the benefits of our business development activities in 2017. On March 1, we completed our acquisition of six ANDAs. Along with several other products in our internal development pipeline, these products provide us with an opportunity to compete in a growing market for niche otic and ophthalmic generic drugs. Amring intends to start marketing and distributing these products in the United States in the coming months.”
Amring Pharmaceuticals is a privately-held generic pharmaceutical company active in global markets geared to supplying unique and specialized products. The company is part of the global Amring Pharmaceuticals business and is partnered with established global biopharmaceutical companies.
Luitpold Pharmaceuticals, Inc., a member of the Daiichi Sankyo Group, develops and markets quality injectable drugs for healthcare professionals, clinics, and hospitals across the United States and Canada. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, also is a member of the Daiichi Sankyo Group.
(Source: PR Newswire)
